Floatz logo

S-Ketamine

Treatment-Resistant Major Depressive Disorder

Hospital Universitari Vall d'Hebron Research InstituteN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Treatment-Resistant Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
MIDAZOLAM
Joshua Rosenblat
Phase 2CCC
TEONANACATL
Kyle Greenway
Phase 2CCC
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Joshua Rosenblat
Phase 2CCC

Same molecule, other indications

S-Ketamine is also rated in:

depressive disorderDormant
A
Indicative ·
81 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
76 / 100
View asset →
depressive disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →